NGAL is an early predictive biomarker of contrast-induced nephropathy in children
Russel Hirsch(National Heart Institute), Prasad Devarajan(Cincinnati Children's Hospital Medical Center), Sudha Dastrala(Cincinnati Children's Hospital Medical Center), Catherine L. Dent(Cincinnati Children's Hospital Medical Center), Holly Pfriem(Cincinnati Children's Hospital Medical Center), Michael Bennett(Associates Research), Janene Allen(Cincinnati Children's Hospital Medical Center), Qing Ma(University of North Carolina at Chapel Hill), Robert H. Beekman(Cincinnati Children's Hospital Medical Center), Mark Mitsnefes(University of Cincinnati)
Cited by 459
Related Papers
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Indications for Cardiac Catheterization and Intervention in Pediatric Cardiac Disease
|Circulation|2011|848
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
|Hepatology|2015|689
The Outcome of Neutrophil Gelatinase-Associated Lipocalin-Positive Subclinical Acute Kidney Injury
|Journal of the American College of Cardiology|2011|685
Age-Specific Reference Intervals for Indexed Left Ventricular Mass in Children
|Journal of the American Society of Echocardiography|2009|567